Results 21 to 30 of about 8,460 (122)
Revista de Gastroenterología de México, 2022 Resumen: La colitis ulcerativa (CU) es una enfermedad crónica de etiología desconocida, incurable, su curso clínico es intermitente, caracterizado por periodos de remisión y recaídas, su prevalencia e incidencia mundial ha venido incrementando.
F. Juliao-Baños +31 more
doaj +1 more source
Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection-Site Reactions. [PDF]
JGH OpenABSTRACT Background/Aims The subcutaneous (SC) formulation of vedolizumab is available as an alternative to the intravenous (IV) formulation in patients with ulcerative colitis (UC). However, data from Asian patients are limited, and the clinical course of injection‐site reactions (ISRs) remains unclear.
Furuya M +3 more
europepmc +2 more sources
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach [PDF]
Intestinal Research, 2018 Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC.
Silvio Danese +11 more
doaj +1 more source
Revista de Gastroenterología de México (English Edition), 2022 Ulcerative colitis (US) is a chronic disease of unknown etiology. It is incurable and its clinical course is intermittent, characterized by periods of remission and relapse. The prevalence and incidence of the disease has been increasing worldwide.
F. Juliao-Baños +31 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, Volume 57, Issue 3, Page 335-344, February 2023., 2023 Odds ratio of alternating disease courses in subsequent pregnancies, UC and CD combined. Odds ratio of experiencing disease activity during pregnancy depending on occurrence of disease activity within 6 months of conception and attainment of remission at time of conception.
Thea Vestergaard +6 more
wiley +1 more source
JGH Open, Volume 6, Issue 9, Page 612-620, September 2022., 2022 Initial steroid dose of ≥30 mg was associated with clinical remission at week 4 in outpatients. Clinical remission at week 4 and the steroid dose reduction rate at week 4 were associated with treatment discontinuation within 12 weeks. Withdrawal of corticosteroids has been become more appropriate in the last 5 years.
Masataka Masuda +9 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, Volume 56, Issue 3, Page 501-509, August 2022., 2022 This cohort study examined the source of steroid prescriptions for Inflammatory Bowel Disease in Leeds and consequences of steroid excess. Patients were more likely to flare after primary care prescriptions. Steroid excess was associated higher risks for hospital admission for IBD, hospital admissions for infections and need for antibiotics ...
Konstantina Rosiou +5 more
wiley +1 more source
Systematic review—pancreatic involvement in inflammatory bowel disease
Alimentary Pharmacology &Therapeutics, Volume 55, Issue 12, Page 1478-1491, June 2022., 2022 Systematic review. Pancreatic involvement in inflammatory bowel disease (IBD). The wide spectrum of pancreatic involvement in patients with IBD may represent a challenge. From the 124 studies analyzed, acute pancreatitis (AP) is the most frequent pancreatic manifestation in IBD; the majority of AP cases in IBD are due to gallstones and drugs, but cases
Sara Massironi +8 more
wiley +1 more source
Revista de Gastroenterología de México, 2020 Resumen: Hasta este momento, la evidencia disponible sugiere que los pacientes con enfermedad inflamatoria intestinal (EII) no tienen un mayor riesgo de desarrollar COVID-19.
J.L. de León-Rendón +2 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, Volume 55, Issue 4, Page 401-411, February 2022., 2022 Defective barrier function is believed to be central to the pathogenesis of inflammatory bowel disease. GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut.
Silvio Danese +15 more
wiley +1 more source